EG 427 Announces New Preclinical Results from Multiple Studies of EG110A in NDO and OAB
January 04, 2024EG 427 reports positive preclinical results from two studies of its gene therapy product EG110A for the treatment of neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
- In a non-clinical pharmacology study in an OAB model, EG110A showed similar efficacy and a strong safety profile compared to botulinum toxin A, notably without the increase in post-void residual urine volume, a known adverse reaction in NDO and OAB with botulinum toxin A
- In a long-term non-clinical kinetic study, EG110A demonstrated persistent transgene expression in the dorsal root ganglia in animals of at least six months
Access full Press Release here
Recent posts
EG 427 Announces Attendance at Conferences in H1 2024
EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters
EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder
EG 427 to hold poster presentation on lead asset EG110A at ESGCT
